Cellect Biotechnology Ltd. (APOP): Price and Financial Metrics
APOP Price/Volume Stats
| Current price | $13.17 | 52-week high | $35.52 |
| Prev. close | $13.12 | 52-week low | $6.64 |
| Day low | $13.10 | Volume | 17,400 |
| Day high | $13.37 | Avg. volume | 479,845 |
| 50-day MA | $19.12 | Dividend yield | N/A |
| 200-day MA | $14.88 | Market Cap | 12.87M |
APOP Stock Price Chart Interactive Chart >
Cellect Biotechnology Ltd. (APOP) Company Bio
Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. The company was founded in 2011 and is based in Kfar Saba, Israel.
Latest APOP News From Around the Web
Below are the latest news stories about Cellect Biotechnology Ltd that investors may wish to consider to help them evaluate APOP as an investment opportunity.
Quoin Pharmaceuticals Announces Signing of Exclusive License from Queensland University of Technology, AustraliaAddition of Bi-Functional Protein Is Complementary to Lead Asset QRX003 for Netherton SyndromeASHBURN, Va., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has signed an agreement with Queensland University of Technology, Australia (QUT). The agreement is for an exclusive option to a bi-functional protein that has shown promising in-vitro data as |
Cellect Biotechnology Announces Record Date and Distribution Date for CVRs in Connection with Strategic Merger with Quoin PharmaceuticalsTel Aviv , Oct. 15, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: “APOP”) (the “Company”), announced today the record date and distribution date for the contingent value rights (the “CVRs”) to be distributed in connection with the previously announced strategic merger with privately-held Quoin Pharmaceuticals, Inc., a specialty pharmaceutical company focused on rare and orphan diseases (the “Merger”) and the sale of the Company’s subsidiary, Cellect Biotherapeutics Ltd., to EnCell |
Short Squeeze Stocks: BMRA, PROG and 3 Other Stocks Experts Think Are Ready to PopAccording to Fintel, these five short squeeze stocks are among the most likely to see a squeeze attempt moving forward. |
36 Stocks Moving In Tuesday's Mid-Day SessionGainers Digital Brands Group, Inc. (NASDAQ: DBGI) shares climbed 39.3% to $4.1090 after the company issued full-year 2022 revenue guidance of $37.5 million to $42.5 million, representing a 350% increase year-over-year. Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) gained 33% to $7.11 after the company announced the OTC consumer launch of Regenacyn Advanced Scar Gel and Ocucyn Eyelid & Eyelash Cleanser on Amazon.com and MucoClyns on Amazon sites in Europe. Gogo Inc. (NASDAQ: GOGO) shares jumped 23. |
Cellect Biotechnology Announces Shareholder Approval of Strategic Merger with Quoin PharmaceuticalsTel Aviv, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), announced shareholders voted to approve the previously announced strategic merger agreement with privately-held Quoin Pharmaceuticals, a specialty pharmaceutical company focused on rare and orphan diseases, and all other proposals presented at the Special General Meeting of shareholders held on September 26, 2021, including the sale of the Companys subsidiary, Cellect Biotherapeutics Ltd, to EnCellX Inc. , a privately held company based in San Diego, CA. |
APOP Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | 71.48% |
| 5-year | -78.83% |
| YTD | N/A |
| 2022 | N/A |
| 2021 | 0.00% |
| 2020 | -2.69% |
| 2019 | -78.86% |
| 2018 | -70.00% |
Loading social stream, please wait...